Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2007 1
2014 2
2015 1
2016 1
2017 1
2018 3
2019 5
2020 4
2021 10
2022 5
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

31 results

Results by year

Filters applied: . Clear all
Page 1
Vemurafenib and Obinutuzumab as Frontline Therapy for Hairy Cell Leukemia.
Park JH, Devlin S, Durham BH, Winer ES, Huntington S, von Keudell G, Vemuri S, Shukla M, Falco V, Cuello B, Gore S, Stone R, Abdel-Wahab O, Tallman MS. Park JH, et al. Among authors: von keudell g. NEJM Evid. 2023 Oct;2(10):EVIDoa2300074. doi: 10.1056/EVIDoa2300074. Epub 2023 Sep 21. NEJM Evid. 2023. PMID: 38320179
Nivolumab for relapsed/refractory classical Hodgkin lymphoma: 5-year survival from the pivotal phase 2 CheckMate 205 study.
Ansell SM, Bröckelmann PJ, von Keudell G, Lee HJ, Santoro A, Zinzani PL, Collins GP, Cohen JB, de Boer JP, Kuruvilla J, Savage KJ, Trněný M, Provencio M, Jäger U, Willenbacher W, Wen R, Akyol A, Mikita-Geoffroy J, Shipp MA, Engert A, Armand P. Ansell SM, et al. Among authors: von keudell g. Blood Adv. 2023 Oct 24;7(20):6266-6274. doi: 10.1182/bloodadvances.2023010334. Blood Adv. 2023. PMID: 37530622 Free PMC article. Clinical Trial.
Outcomes of Patients with Positive Interim Positron Emission Tomography (PET) Continuing ABVD in the Clinical Setting.
Zheng S, Gupta K, Goyal P, Nakajima R, Michaud L, Batlevi CL, Hamlin PA, Horwitz S, Kumar A, Matasar MJ, Moskowitz AJ, Moskowitz CH, Noy A, Palomba ML, Straus DJ, Von Keudell G, Falchi L, Yahalom J, Zelenetz AD, Younes A, Salles G, Schöder H, Joffe E. Zheng S, et al. Among authors: von keudell g. Cancers (Basel). 2023 Mar 14;15(6):1760. doi: 10.3390/cancers15061760. Cancers (Basel). 2023. PMID: 36980646 Free PMC article.
Clinical outcomes with use of radiation therapy and risk of transformation in early-stage follicular lymphoma.
Sha F, Okwali M, Alperovich A, Caron PC, Falchi L, Hamilton A, Hamlin PA, Horwitz SM, Joffe E, Khan N, Kumar A, Matasar MJ, Moskowitz AJ, Noy A, Owens C, Palomba LM, Rodriguez-Rivera I, Straus D, von Keudell G, Zelenetz AD, Yahalom J, Dogan A, Schöder H, Seshan VE, Salles G, Younes A, Batlevi CL. Sha F, et al. Among authors: von keudell g. Blood Cancer J. 2022 Feb 10;12(2):29. doi: 10.1038/s41408-022-00620-w. Blood Cancer J. 2022. PMID: 35145059 Free PMC article.
The metabolic stress-activated checkpoint LKB1-MARK3 axis acts as a tumor suppressor in high-grade serous ovarian carcinoma.
Machino H, Kaneko S, Komatsu M, Ikawa N, Asada K, Nakato R, Shozu K, Dozen A, Sone K, Yoshida H, Kato T, Oda K, Osuga Y, Fujii T, von Keudell G, Saloura V, Hamamoto R. Machino H, et al. Among authors: von keudell g. Commun Biol. 2022 Jan 11;5(1):39. doi: 10.1038/s42003-021-02992-4. Commun Biol. 2022. PMID: 35017636 Free PMC article.
Phase 1/2 study of intratumoral G100 (TLR4 agonist) with or without pembrolizumab in follicular lymphoma.
Halwani AS, Panizo C, Isufi I, Herrera AF, Okada CY, Cull EH, Kis B, Chaves JM, Bartlett NL, Ai W, de la Cruz-Merino L, Bryan LJ, Houot R, Linton K, Briones J, Chau I, von Keudell GR, Lu H, Yakovich A, Chen M, Meulen Jh T, Yurasov S, Hsu FJ, Flowers CR. Halwani AS, et al. Among authors: von keudell gr. Leuk Lymphoma. 2022 Apr;63(4):821-833. doi: 10.1080/10428194.2021.2010057. Epub 2021 Dec 6. Leuk Lymphoma. 2022. PMID: 34865586 Clinical Trial.
Successful implementation of outpatient R ± DHAX (rituximab, dexamethasone, oxaliplatin, cytarabine) for select patients with lymphoma: a single-center experience.
Pak TK, Dixon BN, Buege MJ, Dao PH, Leary MH, Jarrett JC, Duggan TA, Caron P, Falchi L, Hamlin P, Hamilton A, Matasar MJ, Moskowitz A, Noy A, Owens CN, Von Keudell G, Younes A, Zelenetz AD, Kumar A. Pak TK, et al. Among authors: von keudell g. Leuk Lymphoma. 2022 Apr;63(4):876-884. doi: 10.1080/10428194.2021.2002318. Epub 2021 Nov 16. Leuk Lymphoma. 2022. PMID: 34784853
Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma.
Moskowitz AJ, Shah G, Schöder H, Ganesan N, Drill E, Hancock H, Davey T, Perez L, Ryu S, Sohail S, Santarosa A, Galasso N, Neuman R, Liotta B, Blouin W, Kumar A, Lahoud O, Batlevi CL, Hamlin P, Straus DJ, Rodriguez-Rivera I, Owens C, Caron P, Intlekofer AM, Hamilton A, Horwitz SM, Falchi L, Joffe E, Johnson W, Lee C, Palomba ML, Noy A, Matasar MJ, Pongas G, Salles G, Vardhana S, Sanin BW, von Keudell G, Yahalom J, Dogan A, Zelenetz AD, Moskowitz CH. Moskowitz AJ, et al. Among authors: von keudell g. J Clin Oncol. 2021 Oct 1;39(28):3109-3117. doi: 10.1200/JCO.21.01056. Epub 2021 Jun 25. J Clin Oncol. 2021. PMID: 34170745 Free PMC article. Clinical Trial.
Prophylaxis with intrathecal or high-dose methotrexate in diffuse large B-cell lymphoma and high risk of CNS relapse.
Bobillo S, Joffe E, Sermer D, Mondello P, Ghione P, Caron PC, Hamilton A, Hamlin PA, Horwitz SM, Kumar A, Matasar MJ, Batlevi CL, Moskowitz A, Noy A, Owens CN, Palomba ML, Straus D, von Keudell G, Dogan A, Zelenetz AD, Seshan VE, Younes A. Bobillo S, et al. Among authors: von keudell g. Blood Cancer J. 2021 Jun 16;11(6):113. doi: 10.1038/s41408-021-00506-3. Blood Cancer J. 2021. PMID: 34135307 Free PMC article.
31 results